Pharma and healthcare: sector news on Tuesday 3 November 2026
Average tone +2.5 (slightly positive) across 5 companies with relevant coverage, from 46 stories.
How to read a score. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Company by company
| Company | Tone | Stories | What the coverage was about |
|---|---|---|---|
| AstraZeneca | +7.5 | 28 | Coverage was dominated by well-received quarterly results, with several brokers raising price targets and the shares jumping. |
| Haleon | −9.7 | 9 | Coverage centred on Haleon lowering its guidance after a weak cold and flu season and a China setback, which sent the shares sharply lower. |
| GSK | +2.7 | 6 | Coverage was mostly analyst ratings, with a positive Bernstein view offset by two neutral ratings from other brokers. |
| Smith & Nephew | +5.0 | 2 | Coverage was light, centred on a clinic in Pune adopting the CORI robotic system and a market commentary on possible orthopaedics gains. |
| Convatec | +7.0 | 1 | The only substantive coverage was a piece pointing to continued momentum in Convatec's wound-care business, which gives the day a modestly positive lean. |
Strongest stories in the sector
- −10.0 Sharp share price drop was a leading market story
- −10.0 Outlook lowered owing to weak flu season and China softness in quarter
- +10.0 Results calm worries about growth and several brokers raise targets.
- +10.0 Shares rose sharply on the day.
- −10.0 Share price fell as flu medicine demand disappointed
- +9.2 Broker lifts target as pipeline concerns ease.
- +9.2 Drug shows survival benefit in advanced stomach cancer.
- −9.2 Broker lowered its view on the stock
- +8.3 Investors remain supportive after latest update.
- +8.3 Broker keeps buy view and lifts valuation target.
- +8.3 Broker raises target and keeps positive rating.
- +8.3 Broker lifts target citing strong results.
Pharma and healthcare: every day · FTSE 100 overview for the day
Follow by email
A short, free morning email on how the news treated the Pharma and healthcare sector: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.